Pryce, Kerri D.
Serafini, Randal A.
Ramakrishnan, Aarthi
Nicolais, Andrew
Giosan, Ilinca M.
Polizu, Claire
Torres-Berrío, Angélica http://orcid.org/0000-0002-4740-0293
Vuppala, Sreeya
Kronman, Hope
Ruiz, Anne
Gaspari, Sevasti http://orcid.org/0000-0002-0596-4840
Peña, Catherine J. http://orcid.org/0000-0002-2884-5035
Sakloth, Farhana
Mitsi, Vasiliki
van Duzer, John
Mazitschek, Ralph
Jarpe, Matthew
Shen, Li http://orcid.org/0000-0002-5190-2851
Nestler, Eric J. http://orcid.org/0000-0002-7905-2000
Zachariou, Venetia
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS111351, R01NS086444S1, NS086444-07S1)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA047233)
Article History
Received: 27 September 2021
Accepted: 25 April 2023
First Online: 8 June 2023
Change Date: 22 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41593-024-01579-6
Competing interests
: The authors declare no competing interests. V.Z. and K.D.P. are inventors on a provisional patent regarding RBC1HI as part of an agreement between the Icahn School of Medicine at Mount Sinai and Regenacy Pharmaceuticals.